Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › paclitaxel

paclitaxel

29 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of paclitaxel

470 trials tracked of paclitaxel: 133 in phase 3 or 4 and 85 with published results. The most-cited published study has 3324 citations.

470Trials tracked
133Phase 3 & 4
0Recruiting
85With published results
Phase distribution
Phase 4 5 Phase 3 128 Phase 2 285 Phase 1 43 Other / NA 9
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Completed · 3,324 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,828 cited
  3. Phase 3 A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) Completed · 2,662 cited
  4. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,573 cited
  5. Phase 3 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) Completed · 2,143 cited
  6. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed · 1,788 cited
Show 44 more trials
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,496 cited
  2. Phase 3 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] Completed · 1,412 cited
  3. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,356 cited
  4. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,172 cited
  5. Phase 3 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Completed · 1,147 cited
  6. Phase 3 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed · 1,098 cited
  7. Phase 3 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) Completed · 722 cited
  8. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 572 cited
  9. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 503 cited
  10. Phase 3 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Completed · 503 cited
  11. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 417 cited
  12. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 401 cited
  13. Phase 3 A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Completed · 398 cited
  14. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Completed · 392 cited
  15. Phase 3 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed · 336 cited
  16. Phase 3 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Completed · 320 cited
  17. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 305 cited
  18. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 304 cited
  19. Phase 3 A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed · 300 cited
  20. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 291 cited
  21. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 287 cited
  22. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 286 cited
  23. Phase 3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed · 232 cited
  24. Phase 3 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Completed · 231 cited
  25. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 221 cited
  26. Phase 3 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Completed · 207 cited
  27. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 205 cited
  28. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 192 cited
  29. Phase 3 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Completed · 186 cited
  30. Phase 3 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Completed · 166 cited
  31. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 164 cited
  32. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 162 cited
  33. Phase 3 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Completed · 161 cited
  34. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 143 cited
  35. Phase 3 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. Completed · 143 cited
  36. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 143 cited
  37. Phase 3 A Phase III Study of NK105 in Patients With Breast Cancer Completed · 130 cited
  38. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  39. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 113 cited
  40. Phase 3 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Completed · 100 cited
  41. Phase 3 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer Completed · 98 cited
  42. Phase 3 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study Completed · 98 cited
  43. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Completed · 93 cited
  44. Phase 3 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer Completed · 88 cited

Showing the 50 most-cited and recently-updated of 470 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Oncology RCT
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…
Jun 12, 2026
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer
Oncology Sys. Review
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer Expert Review Helps Identify Breast Cancer Spreading to Stomach
This case report describes a 52-year-old woman with metastatic invasive lobular carcinoma that was initially misidentified as primary gastri…
A single patient's case shows how specific lab tests can help doctors distinguish between stomach cancer and metastatic breast cancer.
Frontiers Jun 12, 2026
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
Allergy & Immunology Guideline
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
Frontiers Jun 4, 2026
Sirolimus and paclitaxel-coated balloons show similar outcomes for coronary in-stent restenosis
Cardiology Meta-analysis
Sirolimus and paclitaxel-coated balloons show similar outcomes for coronary in-stent restenosis Sirolimus and paclitaxel balloons show similar results for heart disease
This GRADE-assessed systematic review and meta-analysis of 3,633 participants with coronary artery disease found no notable variations betwe…
Two drug-coated balloons for coronary artery disease work about equally well, a new analysis finds.
Jun 1, 2026
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
Cardiology Sys. Review
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient Docetaxel chemotherapy linked to rare heart attack in breast cancer patient
This case report and literature review examines acute myocardial infarction following docetaxel chemotherapy in a patient with triple-negati…
A rare heart attack occurred after docetaxel chemotherapy in a patient with triple-negative breast cancer. This case review suggests the dru…
Frontiers May 29, 2026
Systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in coronary artery disease
Cardiology Meta-analysis
Systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in coronary artery disease Meta-analysis links drug balloons to higher heart risks
This systematic review and meta-analysis evaluated drug-coated balloons (DCB) versus drug-eluting stents (DES) in 8,123 patients with corona…
A review of 8,123 patients found drug-coated balloons for heart arteries may raise risks of repeat procedures and cardiac death compared to …
Frontiers May 18, 2026
Case report of penpulimab, nab-paclitaxel, and anlotinib in porocarcinoma
Oncology Sys. Review
Case report of penpulimab, nab-paclitaxel, and anlotinib in porocarcinoma Immunotherapy-Chemo Mix Shows Promise Against Stubborn Skin Cancer
This case report and literature review describes a 78-year-old female with porocarcinoma treated with penpulimab plus nab-paclitaxel, then a…
• A rare skin cancer slowed with immunotherapy plus chemo • Helps patients with porocarcinoma lacking treatment options • Still experimental
Frontiers May 11, 2026
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Pulmonology & Critical Care RCT
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
May 1, 2026
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
OB/GYN & Women's Health RCT
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC New drug combo did not extend life for metastatic triple-negative breast cancer patients in this trial
This phase III RCT in 812 patients with previously untreated metastatic triple-negative breast cancer found that adding capivasertib to pacl…
A large global trial found that adding capivasertib to paclitaxel did not improve overall survival for patients with metastatic triple-negat…
May 1, 2026
Paclitaxel-coated balloons and sirolimus-eluting stents in noncomplex coronary bifurcation lesions
Cardiology RCT
Paclitaxel-coated balloons and sirolimus-eluting stents in noncomplex coronary bifurcation lesions Drug coated balloons show similar results for certain artery blockages
This randomized noninferiority trial subgroup analysis evaluated 2,257 participants with de novo coronary lesions.
New data suggests drug coated balloons may work as well as traditional stents for specific types of coronary artery blockages.
Apr 30, 2026
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
Oncology Phase II
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Apr 24, 2026
Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts
Oncology Cohort
Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts New Tool Predicts Breast Cancer Recurrence From Old Slides
This multi-cohort study evaluated histology-derived gene-expression signatures from routine hematoxylin and eosin slides compared with clini…
A simple AI analysis of old biopsy slides can now predict which breast cancer patients face higher risk of recurrence and who truly benefits…
medRxiv Apr 24, 2026

All paclitaxel Articles